Clorox (CLX) Tops Q3 EPS by 6c; Trims FY EPS Outlook, Sees Sales at Top End

Clorox (NYSE: CLX) reported Q3 EPS of $1.37, $0.06 better than the analyst estimate of $1.31. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.51 billion.

"We delivered solid sales growth of 3 percent, with gains in all U.S. segments and in our International segment, behind our 2020 Strategy," said Chairman and CEO Benno Dorer. "Notably, we delivered these results on top of 4 percent sales growth in the year-ago quarter. Our focus on providing superior value to consumers behind differentiated products and brands, including strong investments in innovation, has enabled us to deliver consistent sales growth."

GUIDANCE:

Clorox sees FY2018 EPS of $6.15-$6.30, versus $6.17-$6.37 prior and the consensus of $6.17. Sees 3% sales growth (previously 1% to 3% growth).

For earnings history and earnings-related data on Clorox (CLX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c